GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Deinove SA (XPAR:ALDEI) » Definitions » Total Liabilities

Deinove (XPAR:ALDEI) Total Liabilities : €21.49 Mil (As of Jun. 2022)


View and export this data going back to 2010. Start your Free Trial

What is Deinove Total Liabilities?

Deinove's Total Liabilities for the quarter that ended in Jun. 2022 was €21.49 Mil.

Deinove's quarterly Total Liabilities increased from Jun. 2021 (€19.51 Mil) to Dec. 2021 (€22.41 Mil) but then declined from Dec. 2021 (€22.41 Mil) to Jun. 2022 (€21.49 Mil).

Deinove's annual Total Liabilities increased from Dec. 2019 (€16.99 Mil) to Dec. 2020 (€19.47 Mil) and increased from Dec. 2020 (€19.47 Mil) to Dec. 2021 (€22.41 Mil).


Deinove Total Liabilities Historical Data

The historical data trend for Deinove's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deinove Total Liabilities Chart

Deinove Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.47 15.12 16.99 19.47 22.41

Deinove Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.22 19.47 19.51 22.41 21.49

Deinove Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Deinove's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.334+(4.688+13.386
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=22.41

Total Liabilities=Total Assets (A: Dec. 2021 )-Total Equity (A: Dec. 2021 )
=9.377--13.031
=22.41

Deinove's Total Liabilities for the quarter that ended in Jun. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3.314+(4.852+13.32
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=21.49

Total Liabilities=Total Assets (Q: Jun. 2022 )-Total Equity (Q: Jun. 2022 )
=6.011--15.475
=21.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Deinove Total Liabilities Related Terms

Thank you for viewing the detailed overview of Deinove's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Deinove (XPAR:ALDEI) Business Description

Traded in Other Exchanges
N/A
Address
1682 rue de la Valsiere, Cap Sigma, ZAC Euromedecine II, Grabels, FRA, 34790
Deinove SA is a biotechnology company engaged in the development of technologies and molecules for the health, nutrition and cosmetics industries. It is developing in two areas of activity, New-generation anti-infective ANTIBIOTICS which involves the search for novel anti-infective molecules and the development of new generations of drugs capable of responding to the challenges of antibiotic resistance; and BIOACTIVES, natural active ingredients discovers, develops and produces bioactives, active ingredients of natural origin from its bacterial biodiversity bank, to invent the new generation of sustainable cosmetics and intends to quickly bring its know-how and its products to other fields, such as nutrition and health.

Deinove (XPAR:ALDEI) Headlines

No Headlines